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Background: Podoconiosis is one of the forgotten types of leg swelling (elephantiasis) in the tropics. Unlike the
other, better-known types of leg swelling, podoconiosis is not caused by any parasite, virus or bacterium, but by an
abnormal reaction to minerals found in the clay soils of some tropical highland areas. Non-governmental Organizations
(NGOs) have been responsible for the development of simple treatment methods without systematic evaluation of its
effectiveness. It is essential that a large scale, fully controlled, pragmatic trial of the intervention is conducted. We aim
to test the hypothesis that community-based treatment of podoconiosis lymphoedema reduces the frequency of acute
dermatolymphangioadenitis episodes (‘acute attacks’) and improves other clinical, social and economic outcomes.
Methods/Design: This is a pragmatic, individually randomised controlled trial. We plan to randomly allocate 680
podoconiosis patients from the East Gojjam Zone in northern Ethiopia to one of two groups: ‘Standard Treatment’ or
‘Delayed Treatment’. Those randomised to standard treatment will receive the hygiene and foot-care intervention from
May 2015 for one year, whereas those in the control arm will be followed through 2015 and be offered the
intervention in 2016. The trial will be preceded by an economic context survey and a Rapid Ethical Assessment to
identify optimal methods of conveying information about the trial and the approaches to obtaining informed consent
preferred by the community. The primary outcome will be measured by recording patient recall and using a simple,
patient-held diary that will be developed to record episodes of acute attacks. Adherence to treatment, clinical stage of
disease, quality of life, disability and stigma will be considered secondary outcome measures. Other outcomes will
include adverse events and economic productivity. Assessments will be made at baseline and at 3, 6, 9 and 12 months
thereafter.
Discussion: The evidence is highly likely to inform implementation of the new master plan for integrated control of
Neglected Tropical Diseases (NTDs), in which podoconiosis is identified as one of eight NTDs prioritised for control.
Potentially, an estimated 3 million patients in Ethiopia will therefore benefit from the results of this trial.
Trial registration: International Standard Randomised Controlled Trial Number. Registration number: ISRCTN67805210.
Date of registration: 24 January 2013.
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Table 1 Endpoints
Endpoint details
Primary endpoint Cumulative incidence of ADLA (total number of
incident episodes over the 12-month follow-up
period).
Secondary endpoints Adherence to treatment
Foot washing, use of ointment, use of bandages,
elevation, exercises, use of socks and shoes.
Clinical outcomes:
Clinical stage of diseasea
Lower leg and foot circumferencesb
Presence of mossy changes
Wounds and inter-digital lesions;
Duration of ADLA days
Social outcomes:
Quality of lifec
Perceived stigmad
Economic outcomes:
Economic productivitye
ADLA, acute dermatolymphangioadenitis
aUsing a scale specifically developed for use in podoconiosis patients [22]
bMeasured in centimetres at mid-calf and mid-foot
cUsing validated Amharic translation of Dermatology Life Quality Index [23]
and WHO Disability Assessment Schedule-II (WHODAS-II)
dUsing scale developed to measure stigma among podoconiosis patients (24)
eOther measures of economic vulnerability found to be related to
podoconiosis in economic context survey
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Podoconiosis is a form of lymphoedema (leg swelling)
arising in people going barefoot in highland tropical
areas [1]. It is a significant problem in tropical Africa
where irritant soils have been generated by environmen-
tal conditions of high altitude (>1,000m) and high rain-
fall (>1,000mm per annum), and are farmed by very
poor people who cannot afford shoes or water for wash-
ing [2]. Although rarely a direct cause of mortality, it
disables an estimated 4 million subsistence farmers in
tropical Africa, greatly reducing productivity [3], leading
to significant stigma from the community [4–6] as well
as health professionals [7], and low quality of life [8].
Despite the high impact of podoconiosis on rural farm-
ing communities, treatment has been hampered by mis-
diagnosis (chiefly confusion with filarial lymphoedema)
and fatalism [7]. Only recently has any form of treat-
ment been offered to people with podoconiosis, and this
has grown up from grassroots level without systematic
evaluation.
At present, foot hygiene services are offered to a total
of about 60,000 patients by non-government organisa-
tions in three regions in Ethiopia. While one non-
controlled follow-up study has assessed clinical and
quality of life changes [9], the impact of the intervention
has not yet been evaluated through a formal trial. It is
important that fully controlled evaluation with measure-
ment of a wider range of outcomes now happens, before
the intervention is expanded to an additional 300 wore-
das (districts) in which podoconiosis was found to be
prevalent in a recent nationwide mapping [10]. The evi-
dence generated from this trial will be conveyed through
a dissemination workshop to key government and non-
government stakeholders once analysis is complete and
is highly likely to inform implementation of the new
master plan for integrated control of Neglected Tropical
Diseases (NTDs), in which podoconiosis is identified as
one of 8 NTDs prioritised for control. Potentially, an es-
timated 3 million patients in Ethiopia will therefore
benefit from the results of this trial.Objectives
The primary objective of the trial is to test the hypoth-
esis that community-based treatment of podoconiosis
lymphoedema reduces the frequency of acute dermato-
lymphangioadenitis episodes (ADLA, ‘acute attacks’).
The secondary objective is to test the hypothesis that
community-based treatment of podoconiosis lymphoe-
dema improves other clinical, social and economic
outcomes.Endpoints
The endpoints for this trial are listed in Table 1.Methods/Design
Trial design
This is a pragmatic Randomised Controlled Trial (RCT)
with two arms that will compare podoconiosis lymphoe-
dema management in the community with delayed treat-
ment (as the control).
Study setting
The study will be based at the recently founded Inter-
national Orthodox Christian Charities (IOCC) Debre
Markos Podoconiosis Project [11] in northern Ethiopia.
The protocol will be carried out in Aneded woreda, with
an estimated total population of 89,446 [12], and made
up of 19 kebeles (smallest administrative sub-unit) each
with an average population of approximately 5,000
people and two Health Centres.
Participants
Participants will be drawn from adults aged 18 years and
older registered as affected with podoconiosis in Aneded
woreda, East Gojjam Zone. These patients are represen-
tative of all those in Amhara regional state in northern
Ethiopia, where the prevalence of podoconiosis is esti-
mated as 3.4 % in the adult population [13]. Until 2010,
there was no government or private treatment for podo-
coniosis anywhere in the region. In 2010, a podoconiosis
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200 patients. To date, approximately 1,000 patients have
been treated, and thousands more are on the waiting list
for treatment [13]. Podoconiosis patients from nine
kebeles of Aneded woreda will be invited to participate.
Diagnosis of podoconiosis is currently based on clinical
features: history of aching and burning starting in the
feet, swelling progressing from the forefoot up the leg;
patients must have lived for at least 10 years in commu-
nities 1,500 meters above sea level; and filarial lymphoe-
dema must have been excluded (negative Binax-Filariasis
rapid antigen test). Among people with lymphoedema in
areas in which mass drug administration for lymphatic
filariasis has never occurred, a negative rapid antigen
test has high predictive value for podoconiosis.
Eligibility criteria
The Inclusion, exclusion and withdrawal criteria are pre-
sented in Table 2.
Sensitisation and recruitment procedures
The Rapid Ethical Assessment (REA) has been used
prior to other studies to establish the most appropriate
way of working with podoconiosis communities inTable 2 Inclusion, exclusion and withdrawal criteria
Inclusion criteria
1. Be at least 18-years old
2. Have provided informed consent
3. Have a diagnosis of at least Stage 2 podoconiosis (that is,
podoconiosis lymphoedema) confirmed by the trial team
4. Have a negative ICT card test
5. Intends to remain within the area during the study period
Exclusion criteria
1. Already undertaking self-treatment comparable to the intervention
2. Nodular disease preventing use of shoes (will be referred for
nodulectomy)
3. Complex wounds (will be referred for specialist care in Debre Markos
Hospital)
4. Patient has a history of allergic reaction to treatment materials
5. Mental health or learning disorder affecting ability to adhere with
treatment
6. Physical disability beyond podoconiosis precluding attendance at
group sessions
7. Disease considered by the Trial Co-ordinator to affect ability to self-
treat.
Withdrawal criteria
1. Wishes to withdraw consent to participate in trial
2. Move outside study Woreda
3. Experiences of SAEs considered by trial coordinator to compromise
ability to participate
4. Experiences of SUSARsouthern Ethiopia [14] and Cameroon, and we plan to
use this method in Gojjam before the trial. Rapid Ethical
Assessment is a form of ethnographic assessment
through which information about a community’s views
and perspectives on specific research may be elicited and
used to inform, for example, development of sensitisa-
tion approaches or consent processes [15]. Our sensitisa-
tion and recruitment will be modelled on the results of
the REA, and the format of Information Sheets and
Consent Forms will depend on responses given by par-
ticipants in the REA. Written informed consent will be
obtained from each participant.Community engagement strategy
The clinical service arm of the IOCC Podoconiosis Project
is complemented by extensive community education and
mobilisation aimed at decreasing misconceptions about
disease aetiology and transmission, and stimulating aware-
ness of ways of preventing and treating podoconiosis [11].
In addition, a community sensitisation workshop involving
political, community and religious leaders, government
representatives and local health workers will be con-
ducted. These groups will play an important role in dis-
seminating information about the trial and will act as the
first level of ‘gatekeeping’ to the participants. Engagement
with the community will continue throughout the trial via
the Patient Associations (PAs).
Sample size
We calculated the required sample size based on a mean
(Standard Deviation) baseline incidence of ADLA of 5.6
(4.9) episodes/year reported in a survey conducted in
November 2011 in this population [11]. We assumed a
reduction in ADLA frequency of 28 % (from 5.6 to 4.0
episodes per year). Based on a sample size calculation
for comparison of two means [16], a 90 % power, an α-
level of 0.05, and a 40 % increase to enable adjustment
for four confounders, and 15 % drop-out rate [9], that is,
adjusting the sample size per group (206 × 1.4/0.85), we
would need a total 680 patients: 340 patients in the im-
mediate treatment arm and 340 patients in the control
arm.
Randomisation
Initial community sensitisation through woreda- and
kebele-level officials will be followed by Health Extension
Workers enumerating patients in their respective kebeles
selected for the study in the woreda. All patients
identified by Health Extension Workers (HEWs) will
be visited at home by a data collector and consent re-
quested for preliminary evaluation against the inclu-
sion and exclusion criteria. The data collector will
record potential willingness to take part in the trial,
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the house and local contact information (for example,
kebele office, nearest mobile phone owner). Patients
who appear to be eligible will then be given an ap-
pointment date for enrolment at the nearest health
facility. At enrolment, all patients will be asked for
full consent for the trial; be evaluated against inclusion and
exclusion criteria once more, and ICT tests and baseline
measurements will be carried out. Community Podoconio-
sis Assistants (CPAs), Data Collectors (DCs) and data
supervisors assisted by the study coordinator and data
manager, will enrol patients.
Data collectors will then map these patients by record-
ing Geographic Information System (GIS) coordinates of
their houses, generating a target list of approximately
850 potential trial participants and take consent to
examine each listed patient. If more than one eligible pa-
tient is found in one household, one will be randomly
selected using a lottery method. Using a sample frame of
households within kebeles, a randomisation list will be
prepared by statisticians at Kenya Medical Research
Institute-Wellcome Trust Research Programme (KWTRP).
Patients will be randomised in excess of the required
sample size to allow for those who decline the invita-
tion to participate or who are later found not to fulfil
the inclusion criteria.
Blinding
Given the nature of the intervention, the trial cannot be
blinded. Although data collectors will be independent of
those delivering treatment, they will be able to deduce
the randomization status of participants when they see
the supplies required for treatment. Similarly, statisti-
cians conducting the analysis cannot be blinded. To
minimise bias, an a priori analytical plan will be defined
as the intervention is in progress and will be adhered to.
Study visits
A timeline of the study is presented in Table 3.
Intervention
The intervention in this trial is podoconiosis lymphoe-
dema hygiene and foot-care management. This consists
of monthly group meetings with instruction and prac-
tical demonstration of foot hygiene and foot care by
Community Podoconiosis Assistants (CPAs), supporting
daily self-treatment. In outline, ‘foot hygiene’ comprises
soaking feet, washing with soap, rinsing with clean water,
drying and application of emollient. ‘Foot care’ includes
supervised use of single-layer, non-elastic bandages for
disease stages ≥3; foot and calf exercises; instruction to
practice foot hygiene daily at home; instruction to elevate
the foot of the bed or areas slept on; instruction to use
socks and shoes during waking hours. Those randomisedto immediate treatment will receive a hygiene and foot-
care intervention from December 2014 for one year, while
those randomised to the control arm will be followed
through 2014 and will be offered the intervention in 2015,
unless it has been shown to be ineffective or harmful.
The trial interventions are described in Table 4.
Each patient randomised to the treatment arm will be
allocated one bar of toilet soap (GIV international white)
every month, and rate of use will be monitored at
monthly meetings. In addition, patients will have dis-
pensed 40 gm of Whitfield’s ointment sufficient for daily
application for one month, will be asked to bring used
tubes with any remaining ointment to their group meet-
ing each month, and excess ointment will be recorded.
Patients with stage 3 and greater podoconiosis will each
receive two short-stretch (<80 % stretch) bandages for
each affected foot, one to be worn while the other is be-
ing washed and dried. Under likely home conditions, it
is anticipated that bandages will need replacement after
approximately 6 months. However, the condition of the
bandages will be checked at monthly group meetings,
and replacements given as required. Patients receiving
bandages will also be given temporary, loose-fitting
shoes at the enrolment visit. All patients’ feet will be
measured at 3 months (once the majority of the swelling
is anticipated to have subsided), and they will be given a
pair of strong, closed ‘trainer’ or leather shoes and two
pairs of socks. Patients will be encouraged to wear shoes
all day, every day, no matter what their activities, and
will be shown how to clean and care for their shoes and
socks. We anticipate that high quality shoes will last for
the full year of the trial, while socks will require replace-
ment after 6 months, but the condition of shoes and
socks will be monitored through the monthly meetings.
Soap, Whitfield’s ointment and bandages will be kept
out of the reach of children in a plastic treatment box.
Standard operating procedures fully describe the hy-
giene products, their storage and application to assure
consistency between participants, healthcare workers
and study visits.
Outcomes and measurement
The primary outcome is the total number of ADLA epi-
sodes during the 12-month follow-up period. ADLA epi-
sodes have been demonstrated to be a common
complication of podoconiosis lymphoedema, occurring
on average five times per year, and contributing to an
average 4.4 days off work per episode [13, 17]. They are
highly distinctive to patients, who in the study area, refer
to these episodes as ‘michader’ (‘the blight that casts you
down causing you to spend the night where it hit you’).
Patients describe pain (in inguinal nodes or in the lower
leg), swelling in addition to the ‘normal’ lymphoedema,
and redness of the leg (sometimes as discrete longitudinal
Table 3 Study timeline
Before
enrolment
Enrolment Baseline Visit 1 Visit 2 Visit 3 Visit 4 close-out
Timepoint -t1 0 3 months 6 months 9 months 12 months
Screening X
GIS mapping X
Potential willingness to participate X
Inclusion and exclusion criteria X X
Consent X
Randomisation X
Socio-demographic X X
Economic X X X X
ADLA (recall) X X
ADLA diary X X X X
SAEs X X X X X
DLQI X X X X X
WHO-DAS II X X X
Stigma scale X X X
Clinical stage X X X X X
Mossy lesions X X X
Foot and leg Circumference X X X
Interdigital lesions X X X
Foot care and hygiene intervention (immediate
treatment group)*
*Monthly intervention meetings
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skin peeling towards the end of the episode. Considering
most of the patients are unable to write, the trial team have
designed the diary such that each patient marks a check
mark (✓) or a dash (-) under the boxes corresponding to
drawings showing a healthy patient (working in the field)
and a patient experiencing acute attacks (shown in bed) for
each day of the month. During the pilot phase, patients had
no difficulty in marking the diaries based on their experi-
ences of acute attacks. For the trial, patients will be trained
to complete diaries at the outset and those who may haveTable 4 Trial intervention
Action Necessary items
Soak for 15 minutes Bowl of water
Wash with soap Named brand (GIV international white)
Apply emollient Each patient will be issued with Whitfield’s ointment
Apply bandages For stage ≥3 disease; two short-stretch (<80 % stretc
oedema
Elevation and
exercises
Ankle rotation exercises.
Elevate foot end of sleeping mattress, if used
Use socks and shoes Temporary (tyre) shoes if bandages issued
One pair robust, closed shoes and two pairs of socksdifficulty (including the elderly or visually impaired) will
be requested to have their diaries filled by family members
or neighbours who are able to read and write. In addition,
diaries of patients in the immediate treatment group will
be checked and collected at every monthly intervention
meetings, whereas all diaries of patients in the control
group will be checked for the first month and a random
10 % on subsequent months. Data collectors will discuss
these diaries with patients at the quarterly data collection
visit at home, and discrepancies between diary and recall
will be reconciled.(2 tubes of 20 gm for a period of 1 month)
h) bandages, spiral from foot, overlap 50 %, continue 8-10 cm above
after 3 months of treatment
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internationally validated scales where possible. Where
no internationally validated scale is available, previously
reported questionnaires will be used (Table 1).
Safety
This is a pragmatic trial of hygiene and foot-care inter-
ventions that use household and community care-based
products that are not prescription medical products and
thus are associated with few safety concerns. Nonethe-
less, safety will be carefully monitored to confirm that
there is indeed minimal risk. Adverse events in both
arms will be reported on the case record forms com-
pleted by the data collectors at the quarterly home visits.
Adverse events related to the intervention will be ac-
tively elicited from those randomised to immediate treat-
ment by CPAs at the monthly meetings via specific
questions. The study coordinator will then confirm oc-
currence of events, analyse them and report them by
telephone and email within 24 hours to the Local Safety
Monitors (LSMs), and the investigators who will reach a
consensus on whether a Serious Adverse Event (SAE)
needs further defining as a Suspected and Unexpected
Serious Adverse Reaction (SUSAR) based on the type of
event, the relationship of the event to the time of
administration and the known biology of intervention.
However, adverse events, regardless of relation to the
intervention, will receive treatment accordingly. Any
SUSAR will then be reported within 24 hours of detec-
tion to the Trial Steering Committee, Institutional Re-
view Boards (IRBs), ethics committees and regulatory
authorities in Ethiopia and the United Kingdom.
Adverse event monitoring
We conducted a risk assessment for this trial and
considered whether a Data Safety Monitoring Board
(DSMB) was required. The reason for putting a DSMB
in place is to monitor safety and efficacy outcomes and
consider whether the trial needs to be revised or stopped
early. We concluded that safety events are too unlikely
to indicate that a DSMB should monitor events. On con-
sidering efficacy and whether an interim analysis would
be appropriate to assess whether the question has been
answered earlier than predicted, we also concluded this
was unnecessary. We consider that ending the trial early
following a DSMB assessment of an interim analysis
would be essentially meaningless in this setting because
as of yet, this intervention is not available to the popula-
tion, and therefore, we would be better continuing the
trial to its full power in order to obtain a full data set to
support analysis of the primary and secondary end-
points. Therefore, based on recommendations in articles
on when a DSMB is required, we have put local inde-
pendent safety monitors in place who will review allSAEs immediately on being notified by the study team
and review all adverse events monthly [18, 19].
We anticipate that the hygiene and foot-care interven-
tion will bring clinical improvements to the lower legs
and social and quality of life changes to the patient as a
whole. These will be recorded as part of the assessment
of scientific objectives. Symptom enquiry related to
the primary outcome (ADLA) will also create the op-
portunity to identify unexpected systemic effects of
the intervention.
The standard of comparison or the control arm is de-
layed intervention. If the trial shows benefit with this
intervention, the data will then be used to influence pol-
icy in Ethiopia, and elsewhere, to make this intervention
widely available.
Assessment of quality
The trial will be monitored by staff at the KEMRI-
Wellcome Trust Programme’s Kilifi Clinical Trials
Facility (KCTF), who will perform on-site and database
monitoring. The approach for trial monitoring will in-
clude mentoring and supporting the trial staff and
healthcare workers, working closely with them before,
during and after the trial to help achieve an ethical, safe
and accurate trial that answers the questions set within
this protocol.
Pre-study start site visits will occur before the first
participant is enrolled. Standard Operating Procedures
(SOPs) will be developed followed by a study initiation
visit that will be conducted by the study coordinator and
supported by the monitoring staff from Kilifi. Here, the
SOPs will be used to ‘walk’ through the study with every-
one involved. All trial staff will be trained and certified for
Good Clinical Practice (ICH-GCP). A trial monitoring
plan will be written and signed off by the Trial Steering
Committee. This will detail how many monitoring visits
are planned and specify the key data points that require
checking against source data. The fact that the products
being used are known and safe, the trial is essentially open
and there are no plans for interim analyses, internal moni-
toring being performed by KCTF staff [20] is in accord
with WHO guidance [21].
Data management
All protocol required information will be collected in
Case Report Forms (CRF) designed by the investigators
and KCTF. Data will be collected on paper proformas,
will undergo a quality control step, and then be tran-
scribed direct onto the trial data management system,
OpenClinica. A random 10 % subset will be checked by
the Ethiopia-based Data Manager. Data will be backed
up daily onto secure external hard drives, and uploaded
to the OpenClinica server at weekly intervals. Data man-
agement will be performed by the CTF in Kilifi, who
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(Akaza Research, Waltham, MA). The trial monitor will
visit for source data verification.Statistical methods
Statistical support will be provided by the KEMRI-
Wellcome Trust Programme in Kilifi, Kenya. A detailed
Statistical Analysis Plan will be developed in 2014-15
while the intervention is in process, and will be ap-
proved by the Trial Steering Committee. The main ana-
lysis will be a test of mean number of ADLA events by
each arm over the observation period.
Ethical approval
The study is approved by the Research Governance and
Ethics Committee of the University of Sussex (approval
number 13/107/DAV; approval date: 12/08/2014), Col-
lege of Health Sciences, Addis Ababa University (meet-
ing number 056/2014; protocol number 071/13/SPH;
approval date: 12/01/2014), the Food, Medicine and
Health Care Administration and Control Authority (ref-
erence number 02/6-1/05/39; approval date: 09/04/2014)
and the National Research Ethics Review Committee of
the Ministries of Health and Science and Technology in
Ethiopia (approval number 3-1/794/06; approval date:
02/06/2014).
Discussion
Limited evidence exists for the effectiveness of lymphoe-
dema care similar to that used for filarial lymphoedema.
To date, one non-controlled follow-up study among
podoconiosis patients indicated improvements in quality
of life measures very rapidly (within the first 3 months),
but slower clinical changes (leg circumference and stage
of disease), with statistically significant changes being
observed after 6-9 months of follow-up [9]. However,
there are no published controlled clinical trials investi-
gating the effectiveness of lymphoedema management in
podoconiosis. We have therefore designed a full-scale
trial to interpret the results to understand the timing of
clinical changes and their relationship to psychosocial
changes in order to be able to advise the optimal dur-
ation of supervised treatment. Our study will be the first
fully controlled, pragmatic trial of the intervention, with
measurement of a wider range of outcomes, including
frequency of acute dermatolymphangioadenitis (ADLA)
in podoconiosis lymphoedema. The evidence is highly likely
to inform implementation of the new master plan for inte-
grated control of Neglected Tropical Diseases (NTDs), in
which podoconiosis is identified as one of eight NTDs
prioritised for control. Potentially, an estimated 3 million
patients in Ethiopia will therefore benefit from the results
of this trial.Trial status
The Rapid Ethical Assessment, the economic context
survey and validation of the patient-held diary have all
been completed. Recruitment for the trial commenced
on 8 October 2014.
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